Equities analysts expect Celsion Co. (NASDAQ:CLSN) to post earnings of ($0.31) per share for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Celsion’s earnings, with estimates ranging from ($0.32) to ($0.29). Celsion posted earnings of ($1.96) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 84.2%. The firm is scheduled to announce its next earnings report on Thursday, March 15th.
According to Zacks, analysts expect that Celsion will report full-year earnings of ($2.46) per share for the current fiscal year. For the next year, analysts anticipate that the business will report earnings of ($1.15) per share, with EPS estimates ranging from ($1.21) to ($1.08). Zacks’ EPS calculations are a mean average based on a survey of research firms that that provide coverage for Celsion.
Several equities analysts have recently weighed in on the company. ValuEngine cut Celsion from a “sell” rating to a “strong sell” rating in a research report on Friday, February 2nd. Oppenheimer assumed coverage on Celsion in a research report on Tuesday, November 21st. They issued an “outperform” rating and a $9.00 price target for the company. Finally, Zacks Investment Research upgraded Celsion from a “sell” rating to a “hold” rating in a research report on Tuesday, December 19th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $11.90.
An institutional investor recently bought a new position in Celsion stock. Virtu Financial LLC purchased a new stake in Celsion Co. (NASDAQ:CLSN) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 42,018 shares of the biotechnology company’s stock, valued at approximately $113,000. Virtu Financial LLC owned approximately 0.24% of Celsion as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 3.63% of the company’s stock.
Celsion Company Profile
Celsion Corporation is an oncology drug development company. The Company’s product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Celsion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion and related companies with MarketBeat.com's FREE daily email newsletter.